iBody Inc. is a biotechnology company with a proprietary antibody discovery platform that integrates single-cell analysis technology with a cell-free antibody expression system. This unique approach enables comprehensive and rapid identification of valuable antibodies from the immune systems of animals—antibodies that are often overlooked by conventional methods. The platform is particularly effective in the screening of high-affinity, high-specificity rabbit monoclonal antibodies, achieving a high success rate.
iBody has a proven track record of contract and collaborative research with pharmaceutical and diagnostic companies, and academic institutions in Japan, and is now actively expanding its global presence.
Through its antibody development services, iBody aims to drive innovation in the development of both therapeutic and diagnostic antibodies.
This is some text inside of a div block.
